Tirzepatide 20mg Smartpen Refill

£80.00

Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.

Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist, Tirzepatide accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).

Mechanism of Action

  • GLP-1: Suppresses appetite and increases feelings of fullness after eating.
  • GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.

Benefits

  • Average weight loss of 24.7% after 72 weeks
  • Reduces appetite and cravings
  • Enhances satiety and energy balance
  • Supports fat oxidation and metabolism
  • Improves insulin sensitivity and blood sugar control

 

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use and must not be misused in any way that contravenes MHRA regulations or applicable laws.